Pregnancy in a patient with systemic mastocytosis demands a carefully balanced clinical approach: mast cell–mediated symptoms must be controlled throughout gestation while keeping any potential fetal risk to a minimum.
Management of systemic mastocytosis during pregnancy involves alleviation of symptoms related to mast cell activation with the use of acceptable medications to minimise potential harm to the fetus.
The strategy focuses on avoiding known triggers combined with a prophylactic anti-mediator drug regimen. The full structured protocol — covering the specific agents, their sequencing, and acute event management — is available below.
DOI: 10.6004/jnccn.2018.0088
Management of SM during pregnancy involves alleviation of symptoms related to mast cell activation with the use of acceptable medications to minimize potential harm to the fetus.
Avoidance of known triggers and prophylactic anti-mediator drug therapy (corticosteroids, antihistamines, and epinephrine) are standard approaches during pregnancy and early postpartum period.
View source ↗